These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 36933975)

  • 21. The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis.
    de Wit HM; Te Groen M; Rovers MM; Tack CJ
    Br J Clin Pharmacol; 2016 Jul; 82(1):301-14. PubMed ID: 26935973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The association between sodium glucose cotransporter-2 inhibitors vs dipeptidyl peptidase-4 inhibitors and renal outcomes in people discharged from hospital with type 2 diabetes: A population-based cohort study.
    Ziser KED; Wood S; Tan GSQ; Morton JI; Shaw JE; Bell JS; Ilomaki J
    J Diabetes; 2024 Apr; 16(4):e13507. PubMed ID: 38599885
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Gan S; Dawed AY; Donnelly LA; Nair ATN; Palmer CNA; Mohan V; Pearson ER
    Diabetes Care; 2020 Aug; 43(8):1948-1957. PubMed ID: 33534728
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study.
    Fu EL; Wexler DJ; Cromer SJ; Bykov K; Paik JM; Patorno E
    BMJ; 2024 Jun; 385():e078483. PubMed ID: 38925801
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concomitant Use of Sodium-Glucose Cotransporter 2 Inhibitors and Overactive Bladder Drugs and the Risk of Urinary Tract Infection.
    Bea S; Lee H; Park S; Cho YM; Choi WS; Bykov K; Shin JY
    Clin Pharmacol Ther; 2024 May; 115(5):1132-1140. PubMed ID: 38284421
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SGLT-2 inhibitors and the risk of hospitalization for community-acquired pneumonia: A population-based cohort study.
    Brunetti VC; Reynier P; Azoulay L; Yu OHY; Ernst P; Platt RW; Filion KB
    Pharmacoepidemiol Drug Saf; 2021 Jun; 30(6):740-748. PubMed ID: 33428309
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Nonalcoholic Fatty Liver Disease Among Patients With Type 2 Diabetes.
    Pradhan R; Yin H; Yu O; Azoulay L
    Diabetes Care; 2022 Apr; 45(4):819-829. PubMed ID: 35104330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical inertia among patients with type 2 diabetes mellitus treated with DPP-4i and/or SGLT-2i.
    Lanzinger S; Schmid SM; Welp R; Zimmermann A; Fasching P; Wagner S; Holl RW
    Diabetes Res Clin Pract; 2018 Dec; 146():162-171. PubMed ID: 30367902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk of major adverse limb events in patients with type 2 diabetes mellitus receiving sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: A population-based retrospective cohort study.
    Lee YC; Dong YH; Yang WS; Wu LC; Lin JW; Chang CH
    Front Pharmacol; 2022; 13():869804. PubMed ID: 36176438
    [No Abstract]   [Full Text] [Related]  

  • 30. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with kidney outcomes in patients with type 2 diabetes: A systematic review and network meta-analysis.
    Yang S; He W; Zhao L; Mi Y
    PLoS One; 2022; 17(4):e0267025. PubMed ID: 35421174
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease.
    Tan X; Liang Y; Rajpura JR; Yedigarova L; Noone J; Xie L; Inzucchi S; de Havenon A
    Cardiovasc Diabetol; 2023 Nov; 22(1):319. PubMed ID: 37985992
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Type 2 diabetes and risk of heart failure: a systematic review and meta-analysis from cardiovascular outcome trials.
    Giugliano D; Maiorino MI; Longo M; Bellastella G; Chiodini P; Esposito K
    Endocrine; 2019 Jul; 65(1):15-24. PubMed ID: 31028667
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome.
    Bouzas C; Pastor R; Garcia S; Monserrat-Mesquida M; Martínez-González MÁ; Salas-Salvadó J; Corella D; Goday A; Martínez JA; Alonso-Gómez ÁM; Fernández-Barceló O; Vioque J; Romaguera D; Lopez-Miranda J; Estruch R; Tinahones FJ; Lapetra J; Serra-Majem L; Riquelme-Gallego B; Martín-Sánchez V; Pintó X; Delgado-Rodriguez M; Matía P; Vidal J; Cardenas-Salas JJ; Daimiel L; Ros E; Toledo E; Manzanares JM; Gonzalez-Monge I; Muñoz MÁ; Martinez-Urbistondo D; Tojal-Sierra L; Muñoz-Bravo C; Miralles-Gisbert S; Martin M; García-Ríos A; Castro-Barquero S; Fernández-García JC; Santos-Lozano JM; Basterra-Gortari FJ; Gutiérrez-Carrasquilla L; Guillem-Saiz P; Satorres A; Abete I; Sorto-Sanchez C; Díez-Espino J; Babio N; Fitó M; Tur JA
    Biomed Pharmacother; 2023 May; 161():114561. PubMed ID: 36934556
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
    Li CX; Liang S; Gao L; Liu H
    PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dipeptidyl peptidase 4 inhibitors, sodium glucose cotransporter 2 inhibitors, and glucagon-like peptide 1 receptor agonists do not worsen diabetic macular edema.
    Phu A; Banghart M; Bahrainian M; Liu TYA; Wolf RM; Channa R
    J Diabetes Complications; 2024 Aug; 38(8):108808. PubMed ID: 39018897
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of thyroid cancer associated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: A population-based cohort study.
    Bea S; Son H; Bae JH; Cho SW; Shin JY; Cho YM
    Diabetes Obes Metab; 2024 Jan; 26(1):108-117. PubMed ID: 37735822
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studies.
    Hidayat K; Du X; Shi BM
    Osteoporos Int; 2019 Oct; 30(10):1923-1940. PubMed ID: 31134305
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Health care utilization and costs associated with switching from DPP-4i to GLP-1RA or SGLT2i: an observational cohort study.
    Newman TV; Munshi KD; Neilson LM; Good CB; Swart ECS; Huang Y; Henderson R; Parekh N
    J Manag Care Spec Pharm; 2021 Apr; 27(4):435-443. PubMed ID: 33769857
    [No Abstract]   [Full Text] [Related]  

  • 40. Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes.
    Chang HY; Singh S; Mansour O; Baksh S; Alexander GC
    JAMA Intern Med; 2018 Sep; 178(9):1190-1198. PubMed ID: 30105373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.